The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Erste Group analyst Hans Engel upgraded Amgen (AMGN) to Buy from Hold. Amgen has a higher operating margin and a higher return on equity than ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Leveraging the Accumulus platform, the digitally generated dossier created by Amgen using its proprietary AI and novel Structured Content and Data Management (SCDM) software is being reviewed by the ...

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Cantor Fitzgerald adjusted its outlook on Amgen shares (NASDAQ:AMGN), reducing the price target from the previous $405.00 to $340.00. Despite the lowered price target, the firm maintained its ...

The "Pharmaceutical Review Designations: Trends and Industry Insights" report has been added to ResearchAndMarkets.com's offering.This report investigates review designations in the pharmaceutical ...